Evidence map›Paper›PMID 41210956›Full record

ArticleiScience2025

Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial.

Alex Luedtke, Youyi Fong, Lars van der Laan, Fei Heng, Ying Huang, Yiwen Lu, Chenchen Yu, Lindsay N Carpp, Sanne Roels, Mathieu Le Gars and 59 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

69 authors.

Alex LuedtkeDepartment of Statistics, University of Washington, Seattle, WA 98195, USA.
Youyi FongVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Lars van der LaanDepartment of Statistics, University of Washington, Seattle, WA 98195, USA.
Fei HengDepartment of Mathematics and Statistics, University of North Florida, Jacksonville, FL 32224, USA.
Ying HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Yiwen LuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Chenchen YuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Lindsay N CarppVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Sanne RoelsJohnson & Johnson Innovative Medicine, Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
Mathieu Le GarsJohnson & Johnson Innovative Medicine, Janssen Vaccines & Prevention B.V., 2301 Leiden, the Netherlands.
Griet A Van RoeyJohnson & Johnson Innovative Medicine, Janssen Vaccines & Prevention B.V., 2301 Leiden, the Netherlands.
Daniel J StiehJohnson & Johnson Innovative Medicine, Janssen Vaccines & Prevention B.V., 2301 Leiden, the Netherlands.
Ilse Van DrommeJohnson & Johnson Innovative Medicine, Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
Avi KennyDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC 27710, USA.
Marco CaronePublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Ollivier HyrienVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Victor AyalaBiomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC 20201, USA.
Lakshmi JayashankarBiomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC 20201, USA.
Flora CastellinoBiomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC 20201, USA.
Obrimpong Amoa-AwuaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Manjula BasappaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Britta FlachVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Bob C LinVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Christopher MooreVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mursal NaisanVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Muhammed NaqviVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Sandeep NarpalaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Sarah O'ConnellVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Allen MuellerVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Leo SerebryannyyVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mike CastroVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Jennifer WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Gabrielle DziublaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
April K RandhawaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Michele P AndrasikVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Jenny HendriksJohnson & Johnson Innovative Medicine, Janssen Vaccines & Prevention B.V., 2301 Leiden, the Netherlands.
Carla TruyersJohnson & Johnson Innovative Medicine, Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
Frank StruyfJohnson & Johnson Innovative Medicine, Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
Hanneke SchuitemakerJohnson & Johnson Innovative Medicine, Janssen Vaccines & Prevention B.V., 2301 Leiden, the Netherlands.
Macaya DouoguihJohnson & Johnson Innovative Medicine, Janssen Vaccines & Prevention B.V., 2301 Leiden, the Netherlands.
James G KublinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Kathleen M NeuzilCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Linda-Gail BekkerInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Nigel GarrettCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Sandra W CardosoEvandro Chagas National Institute of Infectious Diseases-Fundação Oswaldo Cruz, Rio de Janeiro CEP 21.040-900, Brazil.
Patrice DelaFontaineDepartment of Medicine, Tulane University, New Orleans, LA 70112, USA.
Craig A MagaretVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Johan VingerhoetsJohnson & Johnson Innovative Medicine, Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
Martin CasapiaFacultad de Medicina Humana, Universidad Nacional de la Amazonia Peru, Iquitos 16004, Peru.
Marcelo H LossoHospital General de Agudos José María Ramos Mejia, Buenos Aires 1221, Argentina.
Susan J LittleDivision of Infectious Diseases, University of California, San Diego, La Jolla, CA 92037, USA.
Aditya GaurDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Edith SwannVaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Christos J PetropoulosLabCorp-Monogram Biosciences, South San Francisco, CA 94080, USA.
Adrian B McDermottVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Jerald SadoffJohnson & Johnson Innovative Medicine, Janssen Vaccines & Prevention B.V., 2301 Leiden, the Netherlands.
Glenda E GrayPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.
Beatriz GrinsztejnEvandro Chagas National Institute of Infectious Diseases-Fundação Oswaldo Cruz, Rio de Janeiro CEP 21.040-900, Brazil.
Paul A GoepfertDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Dean FollmannBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Pavitra RoychoudhuryVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Alexander L GreningerVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Richard A KoupVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Ruben O DonisBiomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC 20201, USA.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Immune Assays Team
Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team
United States Government (USG)/CoVPN Biostatistics Team

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Statistical Methods in HIV Vaccine Efficacy TrialsR37AI054165 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert · 2010 to 2026
$6.7M
NIAID NIH HHS R37 AI054165NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

In Latin American sites of the ENSEMBLE trial of the Ad26.COV2.S vaccine vs. placebo, binding antibodies and neutralizing antibodies measured 4 weeks post-vaccination (∼peak) against circulating lineages (Ancestral, Gamma, Lambda, Mu, Zeta) were assessed as a correlate of risk of, and correlate of protection against, lineage-specific COVID-19. Comparison of lineage-matched controlled vaccine efficacy (VE) curves showed similar relationships across lineages of lineage-specific antibody with VE against lineage-matched COVID-19, supporting a "variant-invariant correlate of protection model" that undergirds immunobridging inferences of efficacy against new variants based on variant-matched neutralizing antibody titers. Lambda departed from this model at undetectable/just-detectable titers: at ∼ peak Reference-specific titers of 2.7 arbitrary units (AU)/mL (just-detectable) and 30 AU/ml, VE against Ancestral COVID-19 was 53.0% (95% CI: 30.7%, 67.9%) and 84.5% (73.6%, 93.0%), respectively; at the same Lambda-specific titers, VE against Lambda COVID-19 was 12.3% (-54.1%, 50.3%) and 91.1% (68.9%, 98.0%). Additional research is needed for Omicron variants.

Indexed as

Immune responseImmunology

Identifiers

PMID41210956
PMCPMC12589887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.